Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Blood

Volumn 112, Issue 8, 2008, Pages 3115-3121

  Barlogie, Bart ^a   Pineda Roman, Mauricio ^a   Van Rhee, Frits ^a   Haessler, Jeff ^b   Anaissie, Elias ^a   Hollmig, Klaus ^a   Alsayed, Yazan ^a   Waheed, Sarah ^a   Petty, Nathan ^a   Epstein, Joshua ^a   Shaughnessy Jr , John D ^a   Tricot, Guido ^a   Zangari, Maurizio ^a   Zeldis, Jerome ^c   Barer, Sol ^c   Crowley, John ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; ANGIOGENESIS INHIBITOR;

ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPATHOLOGY; DISEASE DURATION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; METAPHASE; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOGENETICS; DISEASE FREE SURVIVAL; FOLLOW UP; GENETICS; METABOLISM; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TIME;

ANGIOGENESIS INHIBITORS; CHROMOSOME ABERRATIONS; CYTOGENETICS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; METAPHASE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; REMISSION INDUCTION; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 54049148621     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-145235     Document Type: Article

References (25)

1. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
2. Zangari M, van Rhee F, Anaissie E, et al. Eightyear median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol. 2008;141:433-444.
3. Pineda-Roman M. Zangari M, Haessler J. et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematology. 2008;140:625-634.
4. Jagannath S. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma. 2007;7(suppl):207-214.
5. Pineda-Roman M, Bolejack V, Arzoumanian V, et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol. 2007; 136:393-399.
6. Zhan F, Barlogie B, Arzoumanian V, et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is kinked to good prognosis. Blood. 2007;109:1692-1700.
7. Haessler J; Shaughnessy JD; Zhan E et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007;13: 7037-7079.
8. Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 2008;113:355-359.
9. Barlogie B. Haessler J, Pineda-Roman M, et al. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. Cancer. 2008; 112:2720-2725.
10. Attal M, Harousseau JL, Leyvras S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood. 2006;15: 3289-3294.
11. Attal M, Harousseau JL, Facon T, et al. Intergroupe Francophone du Myelome: single vs double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
12. Pui C-H, Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
13. Shaughnessy J. Zhan F. Burington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109:2276-2284.
14. Zhan F, Barlogie B, Arzoumanian V, et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692-1700.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Gooley TA, Leisering W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
17. Cox DR. Regression tables and life tables. J R Stat Soc B. 1972;34:187-202.
18. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
19. Faderl S, Kantarjan HM. Novel therapies for myelodysplastic syndromes. Cancer. 2004;101:226-241.
20. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465.
21. Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalanbased autotransplants for multiple myeloma linked to poor hematopoietic stem cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood. 2008;111:94-100.
22. Fonseca R, Barlogie B, Bataille R, Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.
23. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase abnormalities especially of chromosome 13 and hypodiploidy assures long term survival in multiple myeloma treated with Total Therapy I: interpreted in the context of gene expression profiling. Blood. 2003; 101:3849-3856.
24. Burington B, Shaughnessy J, Barlogie B, Crowley J. Gene expression profiling (GEP) of purified plasma cells at baseline and 48hr after dexamethasone (D) or thalidomide (T) improve outcome prediction of baseline GEP alone in patients with multiple myeloma (MM) treated with total therapy 2 (TT2) [abstract]. Blood. 2005;106:502a.
25. Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD Jr. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res. 2008:14:4821-4829.